Thrombocytosis in children and adolescents—classification, diagnostic approach, and clinical management Clemens StockklausnerC. M. DuffertOn behalf of THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) Review Article Open access 12 March 2021 Pages: 1647 - 1665
Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience Deniz Goren SahinOlga Meltem AkayFevzi Altuntas Original Article 14 May 2021 Pages: 1667 - 1675
The rare hemoglobin variant Hb Mizuho: report of a Swiss family and literature review Linet NjueCesare MedriAlicia Rovó Original Article Open access 15 February 2021 Pages: 1677 - 1683
Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit? Petro E. PetridesMichael KleinMaria K. Beykirch Original Article Open access 29 May 2021 Pages: 1685 - 1693
Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis Manisha GadgeelBatool AlQanberSüreyya Savaşan Original Article 23 April 2021 Pages: 1695 - 1700
Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients Doaa I. ElzaeemEsmat A. El SharkawiWaleed M. Abd El-Hamed Original Article 13 May 2021 Pages: 1701 - 1709
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome Dolores SubiráCanan AlhanDunia de Miguel Original Article 09 January 2021 Pages: 1711 - 1722
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry Timothy DevosViolaine HavelangeDominik Selleslag Original Article Open access 04 May 2021 Pages: 1723 - 1732
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study Richard GreilAlessandra TedeschiFatih Demirkan Original Article Open access 20 May 2021 Pages: 1733 - 1742
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study Salvatore LeottaUros MarkovicGiuseppe Milone Original Article 28 March 2021 Pages: 1743 - 1753
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma Ryszard SwobodaSebastian GiebelJan Maciej Zaucha Original Article Open access 24 February 2021 Pages: 1755 - 1767
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma María José CejalvoGabriela BustamanteJavier de la Rubia Original Article 22 April 2021 Pages: 1769 - 1778
Characteristics and survival trends in Finnish multiple myeloma patients—a nationwide real-world evidence study Iiro ToppilaTatu MiettinenPekka Anttila Original Article 12 March 2021 Pages: 1779 - 1787
Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience Zi-Liang HouYu KangHuan-Zhong Shi Original Article 14 March 2021 Pages: 1789 - 1801
Oral therapy adherence and satisfaction in patients with multiple myeloma Marine SolanoEtienne DaguindauAnne-Laure Clairet Original Article 03 May 2021 Pages: 1803 - 1813
A novel Twist1/hsa-miR138-5p/caspase-3 pathway regulates cell proliferation and apoptosis of human multiple myeloma Wenjiao QinQin LiuTao Zhang Original Article 09 May 2020 Pages: 1815 - 1824
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) Cyrille TouzeauNadia QuignotGaëlle Désaméricq Original Article Open access 21 April 2021 Pages: 1825 - 1836
Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience Sara ButeraMarco CerranoLuisa Giaccone Original Article Open access 04 May 2021 Pages: 1837 - 1847
Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan Masamichi IsobeTakaaki Konumafor the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation Original Article 23 February 2021 Pages: 1849 - 1861
Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies Christian A. GordilloSapna ParmarRan Reshef Original Article 03 January 2021 Pages: 1863 - 1870
Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia Linus AngenendtIsabel HilgefortChristoph Schliemann Original Article Open access 19 December 2020 Pages: 1871 - 1878
The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen Peng KeXinyou ZhangXiebing Bao Original Article 22 April 2021 Pages: 1879 - 1889
Complete regression of an HCV-associated diffuse large B cell lymphoma achieved by chemoimmuno-free antiviral therapy Xiao-Hong SunLi-Na WangYa-Ming Xi Letter to the Editor 06 January 2021 Pages: 1891 - 1894
HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient Margarete VoigtKonrad SinnUlf Schnetzke Letter to the Editor Open access 14 January 2021 Pages: 1895 - 1897
Chronic active Epstein-Barr virus infection of T cell type presenting with hemophagocytic lymphohistiocytosis in a Caucasian adult Debbie JiangZhao Ming DongNicholas Burwick Letter to the Editor 06 February 2021 Pages: 1899 - 1900
A belated diagnosis of G6PD deficiency in an 81-year-old woman Violaine Tran QuangSihem TarfiOrianne Wagner-Ballon Letter to the Editor 27 January 2021 Pages: 1901 - 1902
Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia Khaled M. MusallamMaria Domenica CappelliniAli T. Taher Letter to the Editor 11 February 2021 Pages: 1903 - 1905
Hepatocellular carcinoma in patients with thalassemia in the post-DAA era: not a disappearing entity Paolo RicchiSilvia CostantiniAldo Filosa Letter to the Editor 13 April 2021 Pages: 1907 - 1910
Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity? Keisuke KidoguchiYasutaka KuniyoshiYuki Kataoka Letter to the Editor 12 April 2021 Pages: 1911 - 1912
Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation Samuel MacyJakob PasswegMichael Medinger Letter to the Editor 03 June 2021 Pages: 1913 - 1915
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial Michael HeuserB. Douglas SmithJorge E. Cortes Correction Open access 12 May 2021 Pages: 1917 - 1918
Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma Ryszard SwobodaSebastian GiebelJan Maciej Zaucha Correction Open access 24 March 2021 Pages: 1919 - 1919